| 杨其亮,倪文骐,朱峰.治疗难治性高血压的新药:aprocitentan[J].中国临床保健杂志,2024,27(4):573-576. |
| 治疗难治性高血压的新药:aprocitentan |
| New treatment for resistant hypertension:aprocitentan |
| 投稿时间：2024-06-16 |
| DOI：10.3969/J.issn.1672-6790.2024.04.032 |
| 中文关键词: 抗高血压药 内皮素受体拮抗剂 高血压,难治性 药理学和毒理学现象 |
| 英文关键词: Antihypertensive agents Endothelin receptor antagonists Hypertension,treatment-resistant Pharmacological and toxicological phenomena 〖FL |
| 基金项目:中央保健科研课题(2024YB04) |
|
| 摘要点击次数: 1053 |
| 全文下载次数: 1332 |
| 中文摘要: |
| aprocitentan(商品名:Tryvio)是一种口服给药的靶向双重内皮素A/B受体(ETA/ETB)拮抗剂,2024年3月19日获美国食品药品监督管理局批准上市,与其他抗高血压药物联合用于治疗成人难治性高血压。该文通过对aprocitentan的作用机制、药物代谢动力学、临床研究、不良反应、特殊人群用药及注意事项的文献查阅,意在为临床治疗难治性高血压提供用药参考。 |
| 英文摘要: |
| Aprocitentan (Tryvio) is an oral medication and an administered dual endothelin A /endothelin B (ETA/ETB) receptor antagonist.It is approved by the U.S.Food and Drug administration (FDA) on March 19,2024.It is used in combination with other antihypertensive drugs,to lower blood pressure in adult patients who are not adequately controlled on other traditional drugs.Through a comprehensive review of the mechanism of action,pharmacokinetics,clinical trials,adverse effects,considerations for specific patient populations,and precautions regarding aprocitentan,this aims to provide clinical physicians with new strategies for the treatment of resistant hypertension(RH). |
|
查看全文
|
| 关闭 |
|
|
|